The Latest Cardiac and Vascular News
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA® (icosapent ethyl) significantly reduces the total ischemic event risk of cardiovascular death, stroke, myocardial infarction (heart […]
Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuvastatin (rosuva) reduced lipid oxidation by 86% and 75%, respectively (p<0.001) DUBLIN, Ireland and BRIDGEWATER, […]
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) — […]
A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% in patients […]
Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several […]
Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection BRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — JAMA Network […]
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with […]
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of […]
Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries in 2022 […]
Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to […]
